Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 2, 2012, Pages 266-271

  Asai, Nobuhiro ^a   Ohkuni, Yoshihiro ^a   Matsunuma, Ryo ^a   Nakashima, Kei ^a   Iwasaki, Takuya ^a   Kaneko, Norihiro ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Amurubicin; elderly; refractory relapsed small cell lung cancer; third line chemotherapy

Indexed keywords

AMURUBICIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RELAPSE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHLEBITIS; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; THIRD LINE CHEMOTHERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84864648737     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.98983     Document Type: Article

References (26)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24: 4539-44.
2. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
3. El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer. Lung Cancer 2007;57(suppl 2):S30-4.
4. von Pawel J, Ardizzoni A, Thatcher N. The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed small cell lung cancer (SCLC): A review of 631 patients treated with iv topotecan in 6 studies. Lung Cancer 2003;41(S2):S235.
5. Johnson DH. Small cell lung cancer in the elderly patient. Semin Oncol 1997;24:484-91.
6. Igawa S, Yamamoto N, Ueda S, Ono A, Nakamura Y, Tsuya A, et al. Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second-and Third-Line Chemotherapy for Small Cell Lung Cancer. J Thorac Oncol 2007;2:741-4.
7. Park S, Ahn MJ, Ahn JS, Lee J, Hong YS, Park BB, et al. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. Lung Cancer 2007;58:116-22.
8. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan vscyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67.
9. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-92.
10. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin in patients with previously or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-53.
11. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, et al. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Coooperative Group. Eur J Cancer 1989;49:4098-102.
12. Hanada M, Mizuno S, Fukushima A, Sasaki Y, Minato K, Bungo M, et al. A new anticancer agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998;89:1229-38.
13. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998;16:121-8.
14. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. In vivo efficacy and tumorselective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 1998;89:1055-60.
15. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998;89:1061-6.
16. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Uptake and intracellular distribution of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells. Jpn J Cancer Res 1990;90:685-90.
17. Obana N, Imagawa S, Nakano Y, Yamamoto M, Noguchi T, Nagasawa T. Hematological aspects of a novel 9-amonanthracycline, amrubicin. Cancer Sci 2003;94:1104-6.
18. Hasegawa Y, Takeda K, Kashii T, Kawano Y, Katayama H, Sumitani M, et al. Clinical Experiences of Amrubicin Hydrochloride Monotherapy in Previous Treated Patients With Small-Cell Lung Cancer. Jpn J Lung Cancer 2005;45:811-5.
19. Shimokawa T, Shibuya M, Kitamura K, Hosomi Y, Hibino S, Ota T, et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009;14:63-9.
20. Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996;14:821-8.
21. Spiegelman D, Maurer H, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung. J Clin Oncol 1989;7:344-54.
22. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcomes in small-cell lung cancer. An analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-74.
23. Gronowitz JS, Bergstrom R, Nou E, Påhlman S, Brodin O, Nilsson S, et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer - A multivariate analysis. Cancer 1990;66:722-32.
24. Osterlind K, Hansen HH, Hansen M, Dombernowsky P, Andersen PK. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants. J Clin Oncol 1986;4:1307-13.
25. Sagman U, Maki E, Evans WK, Warr D, Shepherd FA, Sculier JP, et al. Small-cell carcinoma of the lung: Derivaton of a prognostic staging system. J Clin Oncol 1991;9:1639-49.
26. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of se as a predictor for survival. Br J Cancer 1991;63:986-92.